Amplia Therapeutics just leveled up their fight against pancreatic cancer! Their FAK inhibitor, narmafotinib, showed real promise in early tests on patient-derived cancer cells. Now, they’re teaming up again with Next & Bio to see if combining it with new kRAS inhibitors can pack an even bigger punch. With kRAS mutations in 90% of pancreatic cancers, this could be a game-changer for future treatments. Fingers crossed for more good news at their upcoming conference! #Health #BodyHealth #CancerResearch